Based on this evidence, because high levels of IL-23 were found in patients with autoimmune myocarditis, which proceeded to stimulate T helper cells, determining an increased production and release of IL-17A, a therapy against IL-23 could be effective in blocking or delaying the fibrotic progression of the disease [68]. The gene discussed is IL37; the disease is autoimmune myocarditis.